{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:22:37Z","timestamp":1794640957972,"version":"4.9.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["10085588"],"award-info":[{"award-number":["10085588"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    Despite significant advances in our understanding of Parkinson's disease (PD) over the last three decades, no disease-modifying therapies (DMTs) have been identified. There is considerable effort focused on this goal, but the challenges in achieving it are illustrated by the limited number of DMTs advancing to late-stage Phase 3 clinical testing (see annual\n                    <jats:italic toggle=\"yes\">Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline<\/jats:italic>\n                    publications). The lack of progress towards slowing the disease is further highlighted by the recent disappointing results from high profile, Phase 2\/3 clinical trials for DMTs. In this commentary, we would like to suggest an alternative strategy for identifying DMTs. Specifically, we propose the evaluation of rationally designed combination therapies that target multiple PD etiological factors.\n                  <\/jats:p>","DOI":"10.1177\/1877718x261434686","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:54:18Z","timestamp":1776776058000},"page":"664-667","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rethinking our strategies to develop disease-modifying therapies for Parkinson's: Time for combination therapies?"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5087-8116","authenticated-orcid":false,"given":"Paloma","family":"Fernandez","sequence":"first","affiliation":[{"name":"Cure Parkinson's, London, UK"},{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8473-5297","authenticated-orcid":false,"given":"Rachel M","family":"Hughes","sequence":"additional","affiliation":[{"name":"Cure Parkinson's, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Matthews","sequence":"additional","affiliation":[{"name":"Cure Parkinson's, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Duffen","sequence":"additional","affiliation":[{"name":"Cure Parkinson's, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-3677","authenticated-orcid":false,"given":"Radi","family":"Haloub","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-3966","authenticated-orcid":false,"given":"Anthony H","family":"Schapira","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4664","authenticated-orcid":false,"given":"Simon RW","family":"Stott","sequence":"additional","affiliation":[{"name":"Cure Parkinson's, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Inhibikase Therapeutics Inc. Form 8-K. United States Securities and Exchange Commission https:\/\/www.inhibikase.com\/investors\/sec-filings\/all-sec-filings\/content\/0001193125-25-015648\/0001193125-25-015648.pdf (29 January 2025)."},{"key":"e_1_3_3_3_2","unstructured":"UCB. Press release: findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson\u2019s research program https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program (2024 accessed 19 June 2025)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02808-3"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240272"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0141-x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.034"},{"key":"e_1_3_3_8_2","unstructured":"A Randomised Double-Blind Parallel-Group Placebo-Controlled 60-Week Phase II Clinical Trial of Ambroxol and Doxycycline for Motor Symptoms in Moderate Severity Parkinson\u2019s Disease. ANZCTR \u2013 Registration https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=385904&isReview=true (accessed 19 June 2025)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24790"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105256"},{"key":"e_1_3_3_11_2","first-page":"889","article-title":"Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain\/plasma concentration ratio after 28 days multiple doses in rats using LC-MS\/MS","volume":"26","author":"Ayoub BM","year":"2021","unstructured":"Ayoub BM, Michel HE, Mowaka S, et al. Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain\/plasma concentration ratio after 28 days multiple doses in rats using LC-MS\/MS. Mol Basel Switz 2021; 26: 889.","journal-title":"Mol Basel Switz"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00734.2023"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.04.029"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02543-w"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251316552"},{"key":"e_1_3_3_17_2","first-page":"100645","article-title":"GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues","volume":"6","author":"Bloem BR","year":"2025","unstructured":"Bloem BR, Macklin EA, Schwarzschild MA. GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues. Med N Y N 2025; 6: 100645.","journal-title":"Med N Y N"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261434686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261434686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261434686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:08:46Z","timestamp":1794640126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261434686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/1877718X261434686"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261434686","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}